Science & Technology6 October 20263 min read
Nobel Assembly awards 2026 Medicine Nobel to three scientists for optogenetics
The Nobel Assembly at Karolinska Institutet has awarded the 2026 Nobel Prize in Physiology or Medicine jointly to Karl Deisseroth of Stanford University, Peter Hegemann of Humboldt University of Berlin and Georg Nagel of the University of Würzburg. The prize recognises their discoveries on light-gated ion channels and optogenetics, a technique that uses light to control selected nerve cells. It carries 12 million Swedish kronor (about ₹11.5 crore), shared equally among the three.
What optogenetics does
Optogenetics combines genetic engineering and optics. Light-sensitive proteins called opsins are introduced into genetically selected neurons in living tissue. When light falls on them, these proteins regulate the movement of ions across the cell membrane, which turns the neuron's activity on or off.
The human brain has around 90 billion nerve cells intertwined in complex circuits. Older tools such as electrodes or drugs act bluntly and stimulate broad areas indiscriminately. Optogenetics can switch individual circuits on or off with millisecond precision using flashes of light. In the 1970s, Francis Crick had speculated that, since nerve signals travel extremely fast, light would be an ideal tool to control them.
How the discovery was built
In the 1990s Hegemann studied the microscopic alga Chlamydomonas and observed that light rapidly generated an electrical signal. Hegemann and Nagel, both microbiologists, then identified channelrhodopsins, light-gated ion channels found in algae. Under blue light, a channelrhodopsin acts as a physical gate: it opens, positive ions flow in and an electrical impulse results.
Channelrhodopsin-2 (ChR2) was particularly important because it could open in about 0.2 milliseconds. Experiments showed that transferring its gene into mammalian cells made them light-sensitive. The protein combines light detection and ion-channel activity, so it works as a molecular light switch for electrically active cells.
Deisseroth, a neuroscientist, saw the potential of combining this with genetic targeting of particular neurons. He inserted the algal channelrhodopsin gene into rat neurons and used tiny optical fibres to deliver blue light into the brains of living mice. On activation, the channels opened and triggered electrical impulses, giving precise control over specific circuits and behaviours.
Uses in research and medicine, and limits
The work let researchers move from observing neural activity to testing the causal role of specific neurons and circuits. By switching them on or off, scientists can map circuits behind memory, emotions and movement. The technique has changed research on pain, attention, sleep, memory and social behaviour. By isolating malfunctioning circuits, it also gives insight into schizophrenia, depression, Alzheimer's disease, Parkinson's disease and epilepsy.
Researchers hope it could stimulate the auditory nerve more precisely than current electrical cochlear implants. It is also used to study how the nervous system interacts with other organs, including the heart and the gut's enteric nervous system.
In vision, optogenetics may help patients with retinal disorders such as retinitis pigmentosa. In one translational step, a channelrhodopsin-like protein was introduced into the retina of a blind person, and light stimulation gave enough visual function to locate and pick up nearby objects.
Two hurdles remain for use in humans. Brain cells must be genetically modified to express the light-sensitive protein, which carries clinical risks. And the human skull and scalp block visible light, so reaching deep brain regions currently requires surgically implanted fibre-optic cables, which is invasive.